TRANEXAMIC ACID 500mg. IP + MEFENAMIC ACID 250mg. IP

A combination medicine of anti-fibrinolytic and non-steroidal anti-inflammatory drug, that stops bleeding, reduces mild to moderate pain and inflammation at the injured or damaged site. A safe and effective form of medical therapy in women with menorrhagia. (J T Preston, 1995) Effectively reduces menstrual blood loss in women within ovulatory dysfunctional uterine bleeding. (Radha Rani, 2016) A beneficial drug in a wide range of hemorrhagic conditions. (C J Dunn, 1999) Attenuates the severity of blood loss and dysmenorrhea which is associated with ovulatory dysfunctional uterine bleeding. (Radha Rani, 2016) Exerts a significant effect in reducing the bleeding by 59.3% as compared to tranexamic acid alone (50%), in intrauterine device-induced menorrhagia patients. (Nasrin Saharkhiz, 2017) A safe and highly effective treatment for excessive bleeding. (J. Bonnar and B. L. Sheppard, 1996) Significantly improves the quality of life of women with heavy menstrual bleeding. (Hurskainen, 2012) Has the potential to reduce blood loss in gynecological bleeding disorders, such as heavy menstrual bleeding, postpartum hemorrhage, and bleeding irregularities caused by contraceptive implants. (McCormack, 2012) An effective agent in reducing the severity of blood loss associated with ovulatory dysfunctional uterine bleeding and provides symptomatic improvement for the general health of the patients. (NAJAM R, 2010) Reduces postoperative blood loss and transfusion requirements in several types of surgery. (C J Dunn, 1999) A possible alternative to surgery in menorrhagia, and has been used successfully to control bleeding in pregnancy. (C J Dunn, 1999) A promising therapeutic agent for the management of menorrhagia as it reduces menstrual blood and improves dysmenorrhea. Significantly improves both menstrual blood loss and health-related quality of life in women with heavy menstrual bleeding. Shows significantly greater improvement in mean hemoglobin concentration (37.3%gm/dl) than Tranexamic (27.3% gm/dl). (Radha Rani M. B., 2016)